Trials / Active Not Recruiting
Active Not RecruitingNCT03241537
COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer
Open Label, Randomized Phase III Trial of Hormone Therapy Alone Versus COmbined HOrmone With Radiation Therapy in Clinical Pelvic Lymph Node Metastatic Prostate Cancer (COHORT Trial)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Accepted
Summary
In local advanced prostate cancer patients with clinically positive metastatic regional lymph node, the optimal treatment is still unanswered. For these patients, radiotherapy combined with hormonal therapy or hormonal therapy alone are recommended. Recently, the reports from NCCB and SEER data showed that radiotherapy combined with hormonal therapy have better survivals than hormonal therapy alone. This randomized phase III trial compare hormonal therapy alone with combined hormone with radiotherapy in clinically pelvic lymph node metastatic prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Intensity modulated radiotherapy |
Timeline
- Start date
- 2016-01-15
- Primary completion
- 2026-12-14
- Completion
- 2026-12-14
- First posted
- 2017-08-07
- Last updated
- 2023-11-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03241537. Inclusion in this directory is not an endorsement.